3月7日 - ** 药物开发商Anika Therapeutics ANIK.O股价在下午交易中下跌2.7%至16.54美元
** 公司称已完成 (link) 计划将其 Parcus Medical 业务剥离给 Medacta Group MOVE.S,以专注于骨关节炎疼痛管理的核心透明质酸技术,并扩大其再生解决方案组合
** Anika 称已完成出售,交易完成时收到的现金对价总额未披露
** 公司报告称, (link),计划于 2024 年 10 月剥离 Parcus Medical。
** 在过去 12 个月中,ANIK 下跌了 34.7
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.